We benchmarked 14 GLP-1 telehealth providers in 2026 across pricing, clinician quality, eligibility, medication options, and patient experience. The top ten reflect the programs that earned our top recommendation — in this exact order.
How the field has changed
The 2026 GLP-1 telehealth market looks meaningfully different from the 2024 version that most reader memory still draws from. The compounding cliff, the entrance of three insurance-friendly platforms, and the growing maturity of branded supply chains have re-arranged the leaderboard. Two of the providers that dominated 2024 reader interest no longer place in our top five. Two providers that did not exist 18 months ago are now in our top three.
The top three
- JoinSkinny — the cleanest, fastest end-to-end intake we have tested. The clinician follow-up cadence is consistently within 12 hours, and the dose-titration logic is transparent. Read the full ranking for the complete scorecard.
- Hims & Hers — the most polished mobile experience in the category and the lowest friction reorder workflow. Pricing is in the middle of the pack, but the experience justifies it for most readers.
- Ro Body Program — the strongest insurance pathway for branded GLP-1, with an in-house prior-authorization team that handles paperwork most providers push back to the patient.
How we benchmarked
Every provider passes through the same 28-point rubric described in our methodology. Scoring is rule-based and provider-blind during data collection; we re-verify pricing each month, because the headline number is rarely the real number.
Best value picks
If price is the dominant factor, three programs stand out:
- Mochi Health — best value among self-pay programs, with transparent dose-titration pricing.
- Henry Meds — the simplest flat-monthly billing in the category. No surprise add-ons.
- Future Health — honourable mention for readers who want compounded semaglutide with reliable supply.
For the full ten, scoring rubric, and category-by-category notes, see our complete 2026 Top 10 ranking.
Who to avoid in 2026
Three providers fell out of the top tier this year because of meaningful changes to their model: opaque dose-titration pricing, undisclosed pharmacy partners, or removal of a clinician from the patient-message workflow. We do not name names in this overview, but each one is flagged in their individual review with the specific finding and the date we observed it.